Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

Having wrangled spirulina into making oral biologics, Lumen aims for low cost and high volume

September 4, 2020 6:28 PM UTC

Having turned photosynthetic bacteria into protein production machines, Lumen believes it has cracked the code to making cheap, oral biologics for widespread diseases in the Western and developing worlds.

The company’s $16 million series B round, announced Tuesday, was led by new investor WestRiver Management and returning investor Bioeconomy Capital, and brings its total funding to $68M, including a $20 million series A round and non-dilutive funding from the Bill & Melinda Gates Foundation. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article